Anabolic-androgenic steroids: medical assessment of present, past and potential users.
OBJECTIVE
To document adverse effects of anabolic-androgenic steroid (AAS) use in community-based users attending a medical clinic.


METHODS
Prospective recruitment, questionnaire-based interview, physical examination and investigations, with follow-up, of people who attended, anonymously, an inner-city hospital clinic established specifically to examine AAS use.


METHODS
58 men, comprising 27 past AAS users, 14 present users and 17 potential users (who formed the control group).


METHODS
Clinical adverse effects and abnormal laboratory findings.


RESULTS
Cyclical use of oral and intramuscular, human and veterinary AASs were reported. The most commonly reported source of AASs was friends (59%), gymnasiums (25%) and doctors (14%). The most common reported adverse effects were alterations in libido (61%), changes in mood (48%), reduced testis volume (46%) and acne (43%). Although mean systolic and diastolic blood pressure was not significantly different between groups, five present (29%), 10 past (37%) and one potential user (8%) were hypertensive. Gynaecomastia was found in 10 past users (37%; P<0.01 v. potential users), two present users (12%) and no potential users. Mean testis volume was significantly smaller in present users (18 mL; P<0.02) than in the other groups. Twenty past users (83%), eight present users (62%) and five potential users (71%) had abnormal liver function test results (P=0.5). After discussion of test results, only 11 participants (19%) reported they would not use AASs in the future.


CONCLUSIONS
Adverse effects were reported by or detected in most of the AAS users who attended the clinic. Despite awareness of adverse consequences, most participants planned future use of AASs.
O'Sullivan
A J
AJ
Department of Medicine, St George Hospital, Sydney, NSW.
Kennedy
M C
MC
Casey
J H
JH
Day
R O
RO
Corrigan
B
B
Wodak
A D
AD
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D045930:Anabolic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D009517:New South Wales; D011446:Prospective Studies; D045165:Testosterone Congeners / Q000008:administration & dosage / Q000009:adverse effects*
D045930:Anabolic Agents; D045165:Testosterone Congeners